Neoadjuvant therapy for bladder cancer with active surveillance
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether people with muscle-invasive bladder cancer can safely avoid immediate surgery or radiation after a short course of chemotherapy. Instead, they would be closely monitored and only treated if the cancer comes back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have bladder cancer that has grown into the muscle layer (stage T2-T4a) but has not spread to lymph nodes or other organs.
- You have not had any chemotherapy or immunotherapy for bladder cancer before.
- You are healthy enough to possibly have surgery or radiation, and you can have an MRI of your pelvis.
- You have not had another cancer (except for certain low-risk ones) in the last 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a bladder-sparing approach for people with muscle-invasive bladder cancer that has a variant histology type. The goal is to avoid removing the bladder by using a combination of treatments.
This trial tests a combination of three drugs before bladder removal surgery in people with muscle-invasive bladder cancer. The goal is to see if this combination can shrink the tumor and improve outcomes.
This study looks at how well a standard chemotherapy given before surgery works for muscle-invasive bladder cancer. It aims to see if higher responses lead to better outcomes.
This study compares two approaches for people with intermediate-risk bladder cancer whose urine shows no signs of cancer after surgery. One group will be watched closely (active surveillance), while the other will receive chemotherapy directly into the bladder (intravesical chemotherapy). The goal is to see if surveillance alone can prevent unnecessary treatment while keeping the cancer controlled.
This study watches people with muscle-invasive bladder cancer who choose to keep their bladder after receiving neoadjuvant therapy (treatment before the main treatment). It aims to see how well bladder-preserving treatments like chemoradiation work over time.
This study tests a combination of bladder-sparing treatments for muscle-invasive bladder cancer, including surgery, chemotherapy, immunotherapy, and radiation, followed by maintenance immunotherapy. The goal is to see if this approach can control cancer while preserving the bladder, compared to a watch-and-wait approach.
Hear when a new Muscle-Invasive Bladder Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.